Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease
- 31 August 2008
- journal article
- Published by Elsevier BV in Surgery
- Vol. 144 (2), 269-275
- https://doi.org/10.1016/j.surg.2008.04.009
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group StudyJournal of Clinical Oncology, 2008
- Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered ChemotherapyClinical Cancer Research, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acidOncogene, 2005
- Careful Decoy Receptor Titering is Required to Inhibit Tumor Angiogenesis While Avoiding Adversely Altering VEGF BioavailabilityMolecular Therapy, 2005
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005
- The Neuropilins Multifunctional Semaphorin and VEGF Receptors that Modulate Axon Guidance and AngiogenesisTrends in Cardiovascular Medicine, 2002
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidNew England Journal of Medicine, 1999
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992